收稿日期: 2023-05-03
录用日期: 2023-07-25
网络出版日期: 2023-08-28
基金资助
国家自然科学基金重点国际（地区）合作研究项目(82120108007);国家自然科学基金(82270739);上海市2021年度“科技创新行动计划”优秀学术带头人计划(21XD1402000);上海市科委科技创新行动计划(22140904000);上海市临床重点专科(shslczdzk02502);上海申康医院发展中心“促进市级医院临床技能与临床创新三年行动计划”(SHDC2020CR6017);上海交通大学“交大之星”计划医工交叉研究项目(YG2019ZDA18);上海市教育委员会高峰高原学科建设计划(20152207)
Research progress in the role of gut microbiota in the pathogenesis and treatment of IgA nephropathy
Received date: 2023-05-03
Accepted date: 2023-07-25
Online published: 2023-08-28
Supported by
National Natural Science Foundation of China—Key International (Regional) Joint Research Program(82120108007);National Natural Science Foundation of China(82270739);Shanghai 2021 "Science and Technology Innovation Action Plan" Outstanding Academic Leaders Program(21XD1402000);Science and Technology Innovation Action Plan of Shanghai Science and Technology Committee(22140904000);Shanghai Municipal Key Clinical Specialty(shslczdzk02502);Shanghai Shenkang Hospital Development Center "Three-year Action Plan for Promoting Clinical Skills and Clinical Innovation in Municipal Hospitals"(SHDC2020CR6017);Key Project of Medical Engineering Cross Research Fund for "Star of Jiao Tong University" of Shanghai Jiao Tong University(YG2019ZDA18);Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant Support(20152207)
IgA肾病（IgA nephropathy，IgAN）是全球最常见的肾小球肾炎，病理上以糖基化缺陷IgA1（glycosylation-deficient IgA1，Gd-IgA1）与其特异性抗体（Gd-IgA1-IgG）形成的免疫复合物在肾小球系膜区弥漫沉积为主要特征。尽管Gd-IgA1产生的原因和机制并不清楚，但越来越多的研究发现，产生Gd-IgA1的浆细胞主要来自肠道相关淋巴组织，由此形成“肠肾轴”理论。随之的多项研究发现在IgAN患者与健康人群之间，肠道菌群及其代谢物的组成存在明显差异。进一步研究发现肠道菌群可能参与IgAN发生和疾病进展，且调节肠道微生物的多项干预措施，如益生菌应用、粪便微生物群移植、调节肠道免疫等可用于IgAN的治疗；其中口服布地奈德控释胶囊为靶向回肠末端的肠道局部激素治疗，已被证实可以减少IgAN患者的尿蛋白水平并延缓肾衰。肠道菌群作为IgAN预防、诊断及治疗靶点具有广阔的前景，需要进一步的研究。
李郡如 , 欧阳彦 , 谢静远 . 肠道菌群在IgA肾病发病与治疗中的作用研究进展[J]. 上海交通大学学报（医学版）, 2023 , 43(8) : 1044 -1048 . DOI: 10.3969/j.issn.1674-8115.2023.08.013
As the most common form of glomerulonephritis worldwide, IgA nephropathy (IgAN) is characterized by the diffuse deposition of immune complexes formed by glycosylation-deficient IgA1 (Gd-IgA1) and its specific antibodies (Gd-IgA1-IgG) in the glomerular mesangium. Although the mechanisms of Gd-IgA1 production are still unknown, there is accumulating evidence that Gd-IgA1-producing plasma cells are primarily derived from gut-associated lymphoid tissue, giving rise to the "gut-kidney axis" theory. Further research has discovered that gut microbiota may be involved in IgAN development and progression, and that several interventions to regulate gut microbiota, such as probiotics, fecal microbiota transplantation, and intestinal immunity modulation, may be used in the treatment of IgAN. In patients with IgAN, targeted-release formulation-budesonide has been shown to reduce urinary protein levels and delay kidney progression. Gut microbiota has promising potential as a preventive, diagnostic and therapeutic target for IgAN, and further research is needed.
| 1 | BERGER J, HINGLAIS N. Intercapillary deposits of IgA-IgG[J]. J Urol Nephrol (Paris), 1968, 74(9): 694-695. |
| 2 | PATTRAPORNPISUT P, AVILA-CASADO C, REICH H N. IgA nephropathy: core curriculum 2021[J]. Am J Kidney Dis, 2021, 78(3): 429-441. |
| 3 | GESUALDO L, DI LEO V, COPPO R. The mucosal immune system and IgA nephropathy[J]. Semin Immunopathol, 2021, 43(5): 657-668. |
| 4 | ISHO B, FLORESCU A, WANG A A, et al. Fantastic IgA plasma cells and where to find them[J]. Immunol Rev, 2021, 303(1): 119-137. |
| 5 | OHYAMA Y, RENFROW M B, NOVAK J, et al. Aberrantly glycosylated IgA1 in IgA nephropathy: what we know and what we don't know[J]. J Clin Med, 2021, 10(16): 3467. |
| 6 | FLOEGE J, RAUEN T, TANG S C W. Current treatment of IgA nephropathy[J]. Semin Immunopathol, 2021, 43(5): 717-728. |
| 7 | YANG Y, PALM N W. Immunoglobulin A and the microbiome[J]. Curr Opin Microbiol, 2020, 56: 89-96. |
| 8 | SHAPIRO J M, DE ZOETE M R, PALM N W, et al. Immunoglobulin A targets a unique subset of the microbiota in inflammatory bowel disease[J]. Cell Host Microbe, 2021, 29(1): 83-93.e3. |
| 9 | REHNBERG J, SYMRENG A, LUDVIGSSON J F, et al. Inflammatory bowel disease is more common in patients with IgA nephropathy and predicts progression of ESKD: a Swedish population-based cohort study[J]. J Am Soc Nephrol, 2021, 32(2): 411-423. |
| 10 | KIRYLUK K, LI Y F, SCOLARI F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens[J]. Nat Genet, 2014, 46(11): 1187-1196. |
| 11 | MONTEIRO R C, BERTHELOT L. Role of gut-kidney axis in renal diseases and IgA nephropathy[J]. Curr Opin Gastroenterol, 2021, 37(6): 565-571. |
| 12 | SALLUSTIO F, CURCI C, CHAOUL N, et al. High levels of gut-homing immunoglobulin A+B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients[J]. Nephrol Dial Transplant, 2021, 36(9): 1765. |
| 13 | KANO T, SUZUKI H, MAKITA Y, et al. Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy[J]. Kidney Int, 2021, 100(2): 364-376. |
| 14 | FELLSTR?M B C, BARRATT J, COOK H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial[J]. Lancet, 2017, 389(10084): 2117-2127. |
| 15 | SALLUSTIO F, CURCI C, DI LEO V, et al. A new vision of IgA nephropathy: the missing link[J]. Int J Mol Sci, 2019, 21(1): 189. |
| 16 | HE J W, ZHOU X J, LI Y F, et al. Associations of genetic variants contributing to gut microbiota composition in immunoglobin A nephropathy[J]. mSystems, 2021, 6(1): e00819-e00820. |
| 17 | MONTEIRO R C, RAFEH D, GLEESON P J. Is there a role for gut microbiome dysbiosis in IgA nephropathy?[J]. Microorganisms, 2022, 10(4): 683. |
| 18 | LIANG X L, ZHANG S M, ZHANG D F, et al. Metagenomics-based systematic analysis reveals that gut microbiota Gd-IgA1-associated enzymes may play a key role in IgA nephropathy[J]. Front Mol Biosci, 2022, 9: 970723. |
| 19 | HAN S S, SHANG L, LU Y, et al. Gut microbiome characteristics in IgA nephropathy: qualitative and quantitative analysis from observational studies[J]. Front Cell Infect Microbiol, 2022, 12: 904401. |
| 20 | DE ANGELIS M, MONTEMURNO E, PICCOLO M, et al. Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN)[J]. PLoS One, 2014, 9(6): e99006. |
| 21 | ZHAO J, BAI M, NING X X, et al. Expansion of Escherichia-shigella in gut is associated with the onset and response to immunosuppressive therapy of IgA nephropathy[J]. J Am Soc Nephrol, 2022, 33(12): 2276-2292. |
| 22 | WU H W, TANG D E, YUN M H, et al. Metabolic dysfunctions of intestinal fatty acids and tryptophan reveal immuno-inflammatory response activation in IgA nephropathy[J]. Front Med (Lausanne), 2022, 9: 811526. |
| 23 | ZHENG N Y, FAN J J, WANG B, et al. Expression profile of BAFF in peripheral blood from patients of IgA nephropathy: correlation with clinical features and Streptococcus pyogenes infection[J]. Mol Med Rep, 2017, 15(4): 1925-1935. |
| 24 | MONTEIRO R C, SUZUKI Y. Are there animal models of IgA nephropathy?[J]. Semin Immunopathol, 2021, 43(5): 639-648. |
| 25 | MCCARTHY D D, KUJAWA J, WILSON C, et al. Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy[J]. J Clin Invest, 2011, 121(10): 3991-4002. |
| 26 | ZHOU N, SHEN Y, FAN L R, et al. The characteristics of intestinal-barrier damage in rats with IgA nephropathy[J]. Am J Med Sci, 2020, 359(3): 168-176. |
| 27 | WANG Y, TIAN L L, SUN L, et al. Gut microbes in immunoglobulin A nephropathy and their potential therapeutic applications[J]. Front Med (Lausanne), 2022, 9: 823267. |
| 28 | TAN J X, DONG L Q, JIANG Z, et al. Probiotics ameliorate IgA nephropathy by improving gut dysbiosis and blunting NLRP3 signaling[J]. J Transl Med, 2022, 20(1): 382. |
| 29 | ANTUSHEVICH H. Fecal microbiota transplantation in disease therapy[J]. Clin Chim Acta, 2020, 503: 90-98. |
| 30 | LAURIERO G, ABBAD L, VACCA M, et al. Fecal microbiota transplantation modulates renal phenotype in the humanized mouse model of IgA nephropathy[J]. Front Immunol, 2021, 12: 694787. |
| 31 | ZHAO J, BAI M, YANG X X, et al. Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports[J]. Ren Fail, 2021, 43(1): 928-933. |
| 32 | ZHI W Q, SONG W Z, ABDI SAED Y, et al. Fecal capsule as a therapeutic strategy in IgA nephropathy: a brief report[J]. Front Med (Lausanne), 2022, 9: 914250. |
| 33 | BARRATT J, LAFAYETTE R A, ROVIN B H, et al. Budesonide delayed-release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy[J]. Expert Rev Clin Immunol, 2023, 19(7): 699-710. |
| 34 | BARRATT J, LAFAYETTE R, KRISTENSEN J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy[J]. Kidney Int, 2023, 103(2): 391-402. |
| 35 | CHEMOUNY J M, GLEESON P J, ABBAD L, et al. Modulation of the microbiota by oral antibiotics treats immunoglobulin A nephropathy in humanized mice[J]. Nephrol Dial Transplant, 2019, 34(7): 1135-1144. |
| 36 | DI LEO V, GLEESON P J, SALLUSTIO F, et al. Rifaximin as a potential treatment for IgA nephropathy in a humanized mice model[J]. J Pers Med, 2021, 11(4): 309. |
| 37 | PAPISTA C, LECHNER S, BEN MKADDEM S, et al. Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction[J]. Kidney Int, 2015, 88(2): 276-285. |
/
| 〈 |
|
〉 |